中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝肾综合征门体循环失衡的机制与治疗

杨黎宏 杨晋辉

引用本文:
Citation:

肝肾综合征门体循环失衡的机制与治疗

DOI: 10.3969/j.issn.1001-5256.2021.12.006
详细信息
    通信作者:

    杨晋辉,fish_net5326@163.com

  • 中图分类号: R575.2; R692

Mechanism and treatment of portal-systemic circulatory imbalance in hepatorenal syndrome

  • 摘要: 肝肾综合征是终末期肝病的严重并发症,其发生与门静脉高压、动脉血管扩张、心输出量和有效循环血量减少、肾动脉收缩等全身血流动力学改变,以及门体循环失衡相关。对于肝肾综合征的治疗,目前主要采用血管活性药物、介入等手段改变全身血流动力学、门体循环失衡,及早干预可改善患者预后。

     

  • [1] FAGUNDES C, GINÈS P. Hepatorenal syndrome: A severe, but treatable, cause of kidney failure in cirrhosis[J]. Am J Kidney Dis, 2012, 59(6): 874-885. DOI: 10.1053/j.ajkd.2011.12.032.
    [2] ANGELI P, GARCIA-TSAO G, NADIM MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document[J]. J Hepatol, 2019, 71(4): 811-822. DOI: 10.1016/j.jhep.2019.07.002.
    [3] Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.

    中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
    [4] BIGGINS SW, ANGELI P, GARCIA-TSAO G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(2): 1014-1048. DOI: 10.1002/hep.31884.
    [5] MINDIKOGLU AL, PAPPAS SC. New developments in hepatorenal syndrome[J]. Clin Gastroenterol Hepatol, 2018, 16(2): 162-177. e1. DOI: 10.1016/j.cgh.2017.05.041.
    [6] WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60(1): 197-209. DOI: 10.1016/j.jhep.2013.07.044.
    [7] MAIWALL R, CHANDEL SS, WANI Z, et al. SIRS at admission is a predictor of AKI development and mortality in hospitalized patients with severe alcoholic hepatitis[J]. Dig Dis Sci, 2016, 61(3): 920-929. DOI: 10.1007/s10620-015-3921-4.
    [8] KOSHY AN, FAROUQUE O, CAILES B, et al. Impaired cardiac reserve on dobutamine stress echocardiography predicts the development of hepatorenal syndrome[J]. Am J Gastroenterol, 2020, 115(3): 388-397. DOI: 10.14309/ajg.0000000000000462.
    [9] MA ZH, LEE SS. Cirrhotic cardiopulmonary: Getting to the heart of the matter[J]. Hepatology, 1996, 14: 606-608. DOI: 10.1002/hep.510240226.
    [10] BLENDIS L, WONG F. Is there a cirrhotic cardiomyopathy?[J]. Am J Gastroenterol, 2000, 95(11): 3026-3028. DOI: 10.1111/j.1572-0241.2000.03249.x.
    [11] NAM SW, LIU H, WONG JZ, et al. Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice[J]. Clin Sci (Lond), 2014, 127(8): 519-526. DOI: 10.1042/CS20130642.
    [12] ALQAHTANI SA, FOUAD TR, LEE SS. Cirrhotic cardiomyopathy[J]. Semin Liver Dis, 2008, 28(1): 59-69. DOI: 10.1055/s-2008-1040321.
    [13] WARD CA, LIU H, LEE SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy[J]. Gastroenterology, 2001, 121(5): 1209-1218. DOI: 10.1053/gast.2001.28653.
    [14] FEDE G, PRIVITERA G, TOMASELLI T, et al. Cardiovascular dysfunction in patients with liver cirrhosis[J]. Ann Gastroenterol, 2015, 28(1): 31-40. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.809.2150&rep=rep1&type=pdf
    [15] AMIN AA, ALABSAWY EI, JALAN R, et al. Epidemiology, pathophysiology, and management of hepatorenal syndrome[J]. Semin Nephrol, 2019, 39(1): 17-30. DOI: 10.1016/j.semnephrol.2018.10.002.
    [16] ZHANG HY, HAN DW, WANG XG, et al. Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome[J]. World J Gastroenterol, 2005, 11(4): 567-572. DOI: 10.3748/wjg.v11.i4.567.
    [17] KOSTREVA DR, CASTANER A, KAMPINE JP. Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity[J]. Am J Physiol, 1980, 238(5): R390-R394. DOI: 10.1152/ajpregu.1980.238.5.R390.
    [18] MING Z, SMYTH DD, LAUTT WW. Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: Role of adenosine[J]. Hepatology, 2002, 35(1): 167-175. DOI: 10.1053/jhep.2002.30425.
    [19] JO SK, CHA DR, CHO WY, et al. Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells[J]. Nephron, 2002, 91(3): 406-415. DOI: 10.1159/000064280.
    [20] YAMAGUCHI N, JESMIN S, ZAEDI S, et al. Time-dependent expression of renal vaso-regulatory molecules in LPS-induced endotoxemia in rat[J]. Peptides, 2006, 27(9): 2258-2270. DOI: 10.1016/j.peptides.2006.03.025.
    [21] SANYAL AJ, BOYER T, GARCIA-TSAO G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J]. Gastroenterology, 2008, 134(5): 1360-1368. DOI: 10.1053/j.gastro.2008.02.014.
    [22] MOORE K, JAMIL K, VERLEGER K, et al. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome[J]. Aliment Pharmacol Ther, 2020, 52(2): 351-358. DOI: 10.1111/apt.15836.
    [23] ALESSANDRIA C, OZDOGAN O, GUEVARA M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation[J]. Hepatology, 2005, 41(6): 1282-1289. DOI: 10.1002/hep.20687.
    [24] HEIDEMANN J, BARTELS C, BERSSENBRVGGE C, et al. Hepatorenal syndrome: Outcome of response to therapy and predictors of survival[J]. Gastroenterol Res Pract, 2015, 2015: 457613. DOI: 10.1155/2015/457613.
    [25] YIN W, LI CZ. Efficacy and prognosis of terlipressin for hepatorenal syndrome and its related factors[J]. Chin J Hepatol, 2016, 21(2): 100-104. DOI: 10.3969/j.issn.1008-1704.2016.02.005.

    尹伟, 李成忠. 特利加压素治疗肝肾综合征的疗效、预后及相关影响因素[J]. 中华肝脏病杂志, 2016, 21(2): 100-104. DOI: 10.3969/j.issn.1008-1704.2016.02.005.
    [26] TAN J, TIAN X, HAN Z, et al. Efficacy comparison between noradrenalin and terlipressin in the treatment of hepatorenal syndrome[J]. Med J Wuhan Univ, 2016, 37(3): 485-487. DOI: 10.14188/j.1671-8852.2016.03.033.

    谭洁, 田霞, 韩峥, 等. 去甲肾上腺素与特利加压素治疗肝肾综合征疗效比较[J]. 武汉大学学报(医学版), 2016, 37(3): 485-487. DOI: 10.14188/j.1671-8852.2016.03.033.
    [27] TAN YX, LONG FL, MAO DW, et al. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome: A Meta-analysis[J]. J Clin Hepatol, 2019, 35(10): 2266-2271. DOI: 10.3969/j.issn.1001-5256.2019.10.027.

    覃艳新, 龙富立, 毛德文, 等. 去甲肾上腺素或特利加压素联合白蛋白治疗1型肝肾综合征效果及安全性比较的Meta分析[J]. 临床肝胆病杂志, 2019, 35(10): 2266-2271. DOI: 10.3969/j.issn.1001-5256.2019.10.027.
    [28] ARORA V, MAIWALL R, RAJAN V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure[J]. Hepatology, 2020, 71(2): 600-610. DOI: 10.1002/hep.30208.
    [29] CAVALLIN M, KAMATH PS, MERLI M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial[J]. Hepatology, 2015, 62(2): 567-574. DOI: 10.1002/hep.27709.
    [30] BRENSING KA, TEXTOR J, PERZ J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase Ⅱ study[J]. Gut, 2000, 47(2): 288-295. DOI: 10.1136/gut.47.2.288.
    [31] DENG D, LIAO MS, LUO KS, et al. Ultrasonographic study on renal hemodynamic changes after transjugular intrahepatic portosystemic stent shunt[J]. Chin J Ultrasound Med, 2004, 20(7): 524-527. DOI: 10.3969/j.issn.1002-0101.2004.07.014.

    邓旦, 廖明松, 骆克枢, 等. TIPSS术后肾脏血流动力学改变的超声评价[J]. 中国超声医学杂志, 2004, 20(7): 524-527. DOI: 10.3969/j.issn.1002-0101.2004.07.014.
    [32] PEEYUSH T, SCOTT W, ROWENA C, et al. Reduced inpatient mortality with transjugular intrahepatic portosystemic shunt (TIPS) creation in cirrhotic patients admitted with hepatorenal syndrome[J]. JVIR, 2016, 27(3): S192. DOI: 10.1016/j.jvir.2015.12.496.
  • 加载中
计量
  • 文章访问数:  476
  • HTML全文浏览量:  139
  • PDF下载量:  94
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-08-04
  • 录用日期:  2021-08-04
  • 出版日期:  2021-12-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回